Podcasts about Roche

Airway health is absolutely critical to growth and development.  When our brain isn't getting enough oxygen, we don't sleep, grow or feel as good.  Dr Roche and his wife Kate started the National Tongue Tie Center in Ireland 8 years ago to address this integral part of health.  Now they see patients as a whole person, not just a part of their body.  In this episode Katie Oshita discusses with Dr Roche and Kate why they saw the need for the Center, and how it has changed.  Listen here to learn more about tongue tie in Ireland.Podcast Guest: Dr. Justin Roche is a Consultant Paediatrician and IBCLC with over two decades of experience in the field of tongue tie. He has worked as a consultant in hospital and community paediatric settings and together with Kate he founded the National Tongue tie Centre in Ireland of which he is the Medical Director. At the National Tongue Tie Centre the team provides multidisciplinary care to infants, children and adults. They have developed a pathway of care to bring Functional Frenuloplasty to infants and children from 3 months of age. Having historically used scissors, then diode laser, he has spent years refining his CO2 laser skills to advance surgical technique to work with the tissue planes for selective fascial release. Justin has completed extensive post-graduate training in tongue tie, lectures internationally on the topic and has produced courses to share this knowledge.Kate is the Clinical Director at the National Tongue Tie Centre in Ireland and leads a team of Therapists and Lactation Consultants to provide the highest quality of rehabilitative care to infants, children and adults with oral dysfunctions. She is a Chartered Physiotherapist, IBCLC and Paediatric Feeding Therapist. Having trained at the University of Liverpool, she worked in both Leeds and Southampton, where she led and delivered the regional neonatal service for pre-term and high-risk infants, before moving to Ireland. She is a member of the Irish Society of Chartered Physiotherapists and registered with CORU. Kate has travelled overseas many times over the years to complete further training in Feeding Therapy, Orofacial Myofunctional Therapy and Craniosacral Therapy, and now lectures internationally.Podcast Host: Katie Oshita, RN, BSN, IBCLC has over 25 years of experience working in Maternal-Infant Medicine.  While Katie sees clients locally in western WA, Katie is also a telehealth lactation consultant believing that clients anywhere in the world deserve the best care possible for their needs.  Being an expert on TOTs, Katie helps families everywhere navigate breastfeeding struggles, especially when related to tongue tie or low supply.  Katie is also passionate about finding the root cause of symptoms, using Functional Medicine practices to help client not just survive, but truly thrive. Email katie@cuddlesandmilk.com or www.cuddlesandmilk.com  

It's that time of year again, spooky season!

Zachary Thomas, Clay County Prosecutor, On Death Penalty Sentence For Joshua Roche | 10-9-25See omnystudio.com/listener for privacy information.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Die Schweiz solle sich freiwillig verpflichten, das Handelsdefizit der USA zu verkleinern. Damit ein Deal mit den USA zustande kommt und die 39 Prozent Zölle sinken. Dies sei eine bessere Lösung, als nur in den USA zu investieren, sagt Hans Gersbach, Co-Direktor der KOF der ETH Zürich. Die Pharmafirmen Roche und Novartis wollen je 50 und 23 Milliardenhöhe in den USA investieren. Roche will 12 000 Arbeitsplätze schaffen. Angekündigte 100-Prozent-Zölle auf Pharmaprodukten hat US-Präsident Donald Trump momentan auf Eis gelegt. Was bringen die Investitionsversprechen den Firmen? Was bedeuten sie für die Schweizer Wirtschaft? Der Co-Direktor der Konjunkturforschungsstelle KOF der ETH Zürich, Hans Gersbach, plädiert auf eine branchenübergreifende gesamtschweizerische Zoll-Lösung. Die Schweiz soll den USA anbieten, freiwillig das Handelsdefizit der USA zu senken. Wie könnte dies gelingen? Warum wäre es für die Schweizer Wirtschaft von Vorteil? Was würde es den USA bringen? Hans Gersbach ist zu Gast im Tagesgespräch bei Karoline Arn.

Syrien wählt zum ersten Mal seit dem Kollaps der Assad-Diktatur ein Parlament. Allerdings wählt nicht das Volk, vielmehr bestimmen Wahlgremien die Abgeordneten, welche die Übergangsregierung ernannt hat: Begegnung mit zwei ungleichen Kandidierenden in einem intransparenten Prozess. Alle Themen: (00:00) Intro und Schlagzeilen (01:17) Erste Wahlen in Syrien seit dem Sturz von Assad (06:32) Nachrichtenübersicht (11:43) Tony Blair und der Friedensprozess für Gaza (16:46) Wer folgt auf Antonio Guterres? (21:28) Wie ein Hochhaus der Roche in Basel die Gemüter erhitzt

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Aktien von Roche und Novartis legen zu, Oktoberfest München nach Bombendrohung wieder geöffnet, der Eigenmietwert ist abgeschafft – was nun?, Julie Andrews wird 90

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 26, 2025. In this episode: Pfizer jumps back into obesity with Metsera bid; Roche maps out its obesity ambitions; UniQure's encouraging gene therapy results for Huntington's; BMS plans US pricing for Cobenfy in the UK; and vaccine skepticism affects vaccine commercial prospects. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HCVAK32IGREDHMH5D4I3RFY6AA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Are you a night owl or a morning lark?For many of us the traditional working day just doesn't suit our circadian rhythms. We're called into a meeting or slumped over a desk at 8am but hyper focused as we're about to leave the office and head home. What if work took our biological clocks into account?In this episode I am joined by Camilla Kring, author of Chrono leadership. We talk about the costs of rigidity in work patterns, and what it takes to develop smarter, more flexible arrangements.Camilla's ideas are revolutionary; she talks about taking the bias away from the 5am club and creating better conditions in the workplace for all. Surely that is something we would all want to get behind.So, when do you perform at your best during the day?“Synchronise your work, family, and biological rhythms for real performance.” - CamillaYou'll hear about:·      How circadian rhythms dictate our natural sleep and wake cycles.·      Why understanding your chronotype can enhance productivity.·      The fact most people are not morning persons, yet workplaces favour early risers.·      How living out of sync with your internal clock can harm health.·      Flexibility in work hours can lead to higher productivity and well-being.·      Trust in employees being crucial for implementing flexible work schedules.·      Why synchronising work and family rhythms can improve life quality. More about Camilla:Camilla Kring, as the founder of Super Navigators, has dedicated the last 20 years to helping individuals navigate their lives and organisations create flexible and inclusive work cultures that accommodate different chronotypes and family structures. She has worked across Europe, China, Latin America and the Middle East with companies including Abbott, Medtronic, Roche and Novo Nordisk.Camilla's insights have been featured in the New York Times, the BBC and the Guardian. She is the author of six books and a TEDx speaker. She holds a Master of Science in Engineering and a PhD in work-life balance from the Technical University of Denmark (DTU). Resources:• Profile: https://www.camillakring.com/about-camilla/ • Book - Chronoleadership: https://www.camillakring.com/books/ • Supernavigators services: https://www.supernavigators.com/   My resources:Try my High-stakes meetings toolkit (https://bit.ly/43cnhnQ) Take my Becoming a Strategic Leader course (https://bit.ly/3KJYDTj)Sign up to my Every Day is a Strategy Day newsletter (http://bit.ly/36WRpri) for modern mindsets and practices to help you get ahead.Subscribe to my YouTube channel (http://bit.ly/3cFGk1k) where you can watch the conversation.For more details about me:●      Services (https://rb.gy/ahlcuy) to CEOs, entrepreneurs and professionals.●      About me (https://rb.gy/dvmg9n) - my background, experience and philosophy.●      Examples of my writing https://rb.gy/jlbdds)●      Follow me and engage with me on LinkedIn (https://bit.ly/2Z2PexP)●      Follow me and engage with me on Twitter (https://bit.ly/36XavNI)

Tarkin's Top Shelf is thrilled to welcome ‘Lucas Wars' author Laurent Hopman and illustrator Renaud Roche to the show. Mark and Becca talk with them about their graphic novel biography of George Lucas and his Star Wars journey. Before diving in, the hosts kick things off with some fun Star Wars questions for their guests.   Help us spread the word about the show Click here to subscribe via iTunes Click here to subscribe via RSS Click here to subscribe via Stitcher Click here to subscribe via Google Play Music Feedback and Promotion Follow us on Twitter @TarkinsTopShelf Like us on Facebook: Tarkin's Top Shelf Follow us on Instagram @TarkinsTopShelf Follow us on Threads  Follow us on Bluesky

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

In this episode of the Econ Dev Show, Dane Carlson sits down with Anders Victor, Director of International Business Development for the Economic Development Partnership of North Carolina, to explore how the state positions itself as a global powerhouse for foreign direct investment. Anders shares how North Carolina leverages its international offices, partnerships, and workforce strengths to attract companies like Toyota, Siemens, and Roche, while also tackling challenges around product availability, infrastructure, and talent pipelines. From lessons learned in global competition to the importance of mentorship and cultural adaptability, Anders offers practical and inspiring advice for economic developers everywhere Like this show? Please leave us a review here (https://econdevshow.com/rate-this-podcast/) — even one sentence helps! Ten Actionable Takeaways for Economic Developers Build international presence -- Overseas offices provide credibility, relationships, and cultural expertise. Don't assume awareness -- Many companies don't know your state; make introductions early. Highlight livability -- Migration, lifestyle, and culture are key decision factors alongside tax and cost advantages. Invest in product readiness -- Sites, utilities, and workforce pipelines must be shovel-ready to compete globally. Leverage co-op marketing -- Communities can pool resources to reach new markets and trade shows. Learn from losses -- Map supply chains and know how your region fits into global networks. Embrace cultural differences -- Business norms vary widely; flexibility builds trust. Prioritize mentorship -- Developing young professionals requires exposure and guidance from experienced leaders. Communicate in native languages -- Speaking a client's language strengthens partnerships and reduces friction. Stay resilient and adaptable -- Every project looks different; success comes from meeting companies where they are. Special Guest: Anders Victor.

In der heutigen Folge widmen wir uns der Entwicklung des Roche Südareals. Eben erst hatte die Bau- und Raumplanungskommission Anpassungen am Bebauungsplan gefordert. Wir diskutieren unter anderem über den Abbruch oder Erhalt des Baus 52 von Architekt Roland Rohn, über eine mögliche Verbreiterung der Solitude oder die öffentliche Durchwegung des Areals. WEBSITE www.architekturbasel.ch INSTAGRAM www.instagram.com/architekturbasel FACEBOOK www.facebook.com/archibasel YOUTUBE www.youtube.com/channel/UC6hTXmiATFx-Pp6NodIBLvQ

Hij is vaak voorspeld. Door autojournalisten, door analisten. Telkens wist Elon Musk hem te ontwijken, maar nu lijkt dat lastig. Techbedrijf Xiaomi, slechts een jaar bezig, zou dan toch echt dé Tesla-killer worden.De Chinese autobouwer wil showrooms openen in Europa en zelfs ook auto's willen bouwen op ons continent. Deze aflevering kijken we wat dat voor autobouwers (en Tesla in het specifiek) betekent. Ook duiken we in het aandeel van Xiaomi. Dat is in 12 maanden met bijna 200 procent gestegen.Hebben we het ook over Apple. Dat wil dat Brussel de regels aanpast. Volgens eigen zeggen is de wet digitale markten niet goed voor gebruikers, maar het lijkt er op dat Apple vooral zelf last heeft van de wet.Intel heeft op zijn beurt weer wat nodig van Apple. Geld en een samenwerking om precies te zijn. Rupsje Nooitgenoeg wil namelijk nog meer centjes bij (oud) klanten ophalen.Verder bespreken we het onderzoek dat Brussel doet naar SAP, een Amerikaans onderzoek naar Philips en hun concurrenten, TKH dat iets afsplitst (of toch niet) en je hoort meer over Trump die 'gesaboteerd' wordt. See omnystudio.com/listener for privacy information.

The FDA is working to reapprove GSK's long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developmental delays with autistic features.” This immediately followed a much-anticipated press conference in which President Donald Trump, flanked by Health Secretary Robert F. Kennedy Jr and other healthcare administrators, linked the use of Tylenol during pregnancy to rising rates of autism.  Meanwhile, Pfizer woke us all up Monday with the news that it had acquired breakout obesity rockstar Metsera for $4.9B. The deal should pump new life into Pfizer's portfolio, which over the last two years has suffered three discontinued assets. Bite-sized deals—or those at or below the $5 billion mark—have defined biopharma recently, with Roche picking up metabolic dysfunction-associated steatohepatitis biotech 89bio for a potential $3.5 billion last week and Novartis putting another $5.7 billion on the line with partner Monte Rosa Therapeutics in a second molecular glue agreement.  Another therapeutic space primed for M&A action is psychedelics. After AbbVie bought Gilgamesh Pharmaceuticals' lead depression asset for $1.2B last month, BioSpace spoke sought opinions from experts on who might be next to take the plunge. A few potential names included Eli Lilly, Bristol Myers Squibb and Merck.  On the policy front, the CDC's revamped vaccine advisory committee convened for their first meeting to discuss COVID-19, MMRV and hepatitis B vaccine schedules. Industry watchers who spoke to BioSpace commented on the “lack of knowledge” and dearth of previous experience on the committee. And while the advisors ultimately voted to change the schedule for the MMRV vaccine, it appears unlikely to significantly affect manufacturers' bottom lines. Finally, in rare disease, Stealth BioTherapeutics secured its long-sought approval for elamipretide—now Forzinity—in Barth syndrome—a disorder that would fall under the purview of the FDA's new Rare Disease Evidence Principles framework for ultra rare diseases affecting less than 1,000 people in the U.S. And we said “Bye Bye Bluebird,” as the famed gene therapy biotech—which was recently bought out by two private equity firms—returned to its original moniker, Genetix Biotherapeutics.  Lastly, make sure to sign up for Biopharm Executive here for access to a special deep dive into China biopharma.  

It's hoped Pharmac's latest funding proposal will save hospitals and patients valuable time. It's looking at funding five new medicines - for breast cancer, multiple sclerosis, eye conditions, and lung cancer. The proposal includes a new under the skin injection treatment, which could replace some IV infusions. Roche New Zealand Country Medical Director Dr Kerryn Symons says the injection takes just a few minutes, when infusions usually take several hours. "Our calculations show that over a period of five years, that the number of hours released in the infusion clinics is about 45,000." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Moog Inc. (MOG.A) - Pat Roche, CEO; Jennifer Walter present at the Gabelli 31st Aerospace & Defense Symposium; introduced by Michael Burgio (Research Analyst). To learn more about Gabelli Funds' fundamental, research-driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com. Connect with Gabelli Funds: • X - https://x.com/InvestGabelli • Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/investgabelli/ http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)

Die ganze Analyse zu Scout24 und der Autoaktien-Welt gibt's in unserem neuen Podcast. Eigentlich hinter PayWall, weil wir dort jede Woche neue, tiefgehende Inhalte produzieren. Aber hier könnt ihr einen Monat kostenlos testen: https://herohero.co/oaws/invites/VTXFVYNWBH. Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Roche hat Abnehmspritze. Pfizer kauft Metsera. Compass kauft Anywhere. Oracle programmiert TikTok. Kenvue und Indiens IT fallen. Samsung kriegt NVIDIA-Go. NVIDIA investiert in OpenAI. Buffett verkauft BYD. Porsche (WKN: PAG911) macht eine Kehrtwende bei Verbrennern. Ist das die richtige Entscheidung? Der Auto-Analyst Jürgen Pieper ist davon überzeugt. Fondsmanager Felix Gode ist bullish bei Scout24 (WKN: A12DM8) und teilt seine Wachstums- und Margenprognosen. Diesen Podcast vom 23.09.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Luis García Langa, analista en Luisgarcialanga.com, pone el foco en Porsche, Wolkswagen, Roche, CapGemini y las acciones relativas con el deporte.

In this episode, we sit down with veteran coach Eoin Roche to explore the nuanced world of athletic development. Eoin, known for his work with various teams from youth development to senior inter-county, dives deep into how he leverages one-on-one sessions and film analysis to unlock player potential.Discover why a one-size-fits-all approach doesn't work in coaching, and how adapting your methods to individual athletes, even using technology to connect with quieter players, can lead to significant breakthroughs. Eoin shares his powerful insights on objective post-game analysis, stressing the importance of data and film over personal biases to find the true story of a performance.You'll also hear about his innovative approach to introducing performance analysis to young athletes, proving that early exposure can create "sponges" eager to learn. Perhaps most importantly, Eoin reveals the vital role of building genuine relationships with players. Learn how showing you care and are invested—through your hard work and commitment—builds invaluable credibility and earns player buy-in.Whether you're a seasoned coach, an aspiring analyst, or just passionate about sports, Eoin's practical wisdom on balancing data, human connection, and making the game fun will resonate deeply.Key Discussion Points:Adapting coaching for individual needsLeveraging technology for film review and player engagementThe power of objective data vs. personal biases in analysisIntroducing performance analysis to youth athletesBuilding credibility and relationships with playersMaking coaching and learning enjoyableDon't miss this engaging conversation that goes beyond the playbook to explore what truly drives Join the new TOC Coach community: https://www.skool.com/toccoach/aboutSubscribe to the Team Culture Toolbox Newsletter so you don't miss the notes to this and every episode! https://www.tocculture.com/newsletter Learn More and Apply for the next TOC Coaching Retreat: https://www.tocculture.com/retreat Interested in booking TOC for a team meeting/consultation? Click here→ https://www.tocculture.com/contactTOC Coaching & Culture Certification : https://www.tocculture.com/offers/3FEMNae2/checkoutLearn More about TOC and how we can help enhance your coaching experience https://www.tocculture.com/Learn More about Besty Butterick and her work with coaches! https://betsybutterick.com/Follow Us On Social MediaSubstack: https://substack.com/@jpnerbuntocInstagram- https://www.instagram.com/tocculture/ TikTok- https://www.tiktok.com/@tocculture Youtube- https://www.youtube.com/@tocculture

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, alleging that Health Secretary Robert F. Kennedy Jr. accused CDC employees of "killing children." In other news, Roivant and Pfizer's therapy shows promise in a rare inflammatory condition, BMS and Novo Nordisk have announced layoffs in New Jersey, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. Additionally, Lexicon has backed phase III decision for a non-opioid pain medication, and Rosnilimab shows promise as a potential next-generation treatment for rheumatoid arthritis. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies like Arsenal and X4 laying off staff to cut costs.The FDA is cracking down on pharmaceutical advertisements in a new regulatory initiative, targeting loopholes in direct-to-consumer ads. Experts believe the FDA is focusing on the wrong issues and should instead address the lack of regulations for compounder drug ads. Akeso, a biotech company in China, has seen success under CEO Michelle Xia's leadership. Other news in the pharmaceutical industry includes the rise of predictive care powered by consumers and AI, ongoing prescriptions of Sarepta's DMD gene therapy despite safety concerns, and companies like Sanofi pulling back from the UK market. Pharma companies are facing challenges in navigating uncertain times amidst layoffs and regulatory crackdowns. Stay tuned for more updates on the latest developments in the industry.

Aktien hören ist gut. Aktien kaufen ist noch besser. Unser Partner Scalable Capital ist jetzt eine Bank und bietet euch dadurch jetzt noch bessere Konditionen. Mehr Infos findet ihr unter: scalable.capital/oaws. NVIDIA pusht Intel. Trump freut's. Deutsche Halbleiter auch. Novo Nordisk freuen Abnehmpillen. Roche kauft 89bio. Axon kauft vielleicht auch. Netskope geht an Börse. CrowdStrike ist Optimist. DogeCoin ist Highflyer. Sind Reifen ein geiles Business? Continental (WKN: 543900) denkt ja. Deshalb ist Aumovio (WKN: AUM0V1) raus. BYD (WKN: A0M4W9) fällt und fällt. Ist das eine Buy-The-Dip-Chance? Der Auto-Experte Jürgen Pieper ist skeptisch. Außerdem teilt er seine Einschätzung zu Xiaomi (WKN: A2JNY1) und Xpeng (WKN: A2QBX7). Diesen Podcast vom 19.09.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

On this week's episode, Daphne Zohar, Josh Schimmer, Luba Greenwood and Matt Gline open with a look at overall market sentiment, spotlighting Stifel's bullish report on the biotech sector's nice recovery since April's “liberation day” with the XBI up over 40%, the recent wave of M&A activity, and the Biotech Winter. The co-hosts then highlight recent deals, including Roche's $3.5 billion acquisition of 89Bio and Novartis's $5.7 billion licensing agreement with Monte Rosa Therapeutics. In data news, the group overviews aTyr Pharma's Phase 3 results in pulmonary sarcoidosis, with Matt Gline sharing perspective on the therapeutic area after Roivant's similar fate. Next, long-versus-short dynamics around biotech data readouts are highlighted, along with positive data sets from Areteia and Apollo. Matt also details Roivant's positive Phase 3 results in dermatomyositis. The conversation then turns to big pharma's exodus from the UK, as several companies including Merck, AstraZeneca, and Eli Lilly scale back large investments. The co-hosts explore possible causes for the pullback, such as heavy regulation and tax incentives holding back innovation. Michal Preminger joins the discussion to share her unique insights on UK and US biotech hubs and draws attention to the Massachusetts paradox and the impact on the biopharma industry. *This episode aired on September 19, 2025

Miramos con lupa a Aumovio, SAP, ST Microelectronics, Roche y la británica Next, de la mano de Juan José del Valle, responsable de análisis de Activotrade.

What if the spaces we design could actively reduce stress and promote healing? In this episode of I Hear Design, interiors+sources Editor-in-Chief Carrie Meadows sits down with Janet Roche and Christine Cowart, co-founders of the Trauma Informed Design Society, to explore the growing movement of trauma-informed design. They discuss the science behind stress and the built environment, the importance of designing with fidelity, and how research, consulting, and education are advancing the field. Listeners will gain insights into how trauma-informed principles can be applied across sectors—from schools and healthcare to workplaces and community spaces—to create environments that improve health, safety, and overall well-being. Whether you're an architect, designer, educator, or advocate, this conversation offers a roadmap for transforming design into a force for resilience and care. Interested in learning more? Purchase a copy of Roche and Cowart's new book, Trauma-Informed Design, here.

Join us for a fascinating conversation with Eoin Roche, a seasoned Hurling coach from Ireland, as he reveals his innovative strategies for athlete development and performance analysis. Eoin, who seamlessly combines coaching with analytical insights, explains why this integrated role is crucial for clarity and effectiveness, especially in amateur sports like GAA where time is precious.Learn how Eoin tackles the challenge of engaging diverse athletes in film sessions, advocating for brief, impactful reviews over lengthy ones. He dives into the importance of establishing core "principles of play" to ensure consistent messaging, and shares powerful techniques like leveraging player-led presentations, strategic questioning ("Why?" and "What did you see?"), and constructive feedback.This episode is packed with practical wisdom for any coach, sports leader, or athlete looking to optimize learning, build confidence, and drive sustained performance. Tune in to transform your approach to team development!Subscribe to the Team Culture Toolbox Newsletter so you don't miss the notes to this and every episode! https://www.tocculture.com/newsletter Learn More and Apply for the next TOC Coaching Retreat: https://www.tocculture.com/retreat Listen to the Culture Builders Podcast: Youtube | SpotifyInterested in booking TOC for a team meeting/consultation? Click here→ https://www.tocculture.com/contactTOC Coaching & Culture Certification : https://www.tocculture.com/offers/3FEMNae2/checkoutLearn More about TOC and how we can help enhance your coaching experience https://www.tocculture.com/Learn More about Besty Butterick and her work with coaches! https://betsybutterick.com/Follow Us On Social MediaSubstack: https://substack.com/@jpnerbuntocInstagram- https://www.instagram.com/tocculture/ TikTok- https://www.tiktok.com/@tocculture Youtube- https://www.youtube.com/@tocculture

Eine knappe Mehrheit der zuständigen Grossratskommission will, dass der Bau 52 erhalten bleibt, der Phamakonzern will ihn abreissen. Wochengast: Der abtretende UPK-CEO Michael Rolaz redet über Veränderungen in der Psychiatrie und seine herausforderndste Zeit in Basel - als ein UPK-Patient auf Freigang im Breite-Quartier mutmasslich eine Frau tötete.

This week on Skytalkers we are so thrilled to talk to the author and illustrator of the graphic novel, “Lucas Wars”, Laurent Hopman and Renaud Roche! In the interview we discuss:  The inspiration behind creating a graphic novel about George Lucas and the creation of Star Wars  The artistic decisions behind choosing which moments of George's life to highlight  How color plays a role in telling George's story throughout the graphic novel  The research and passion that Laurent and Renaud both brought to the project with their love of Star Wars  …and much, much more!  Click here to purchase “Lucas Wars”: https://amzn.to/4plEmX2 Join our Patreon community and unlock bonus episodes + more! Our website! Follow us on Twitter/X @skytalkerspod Follow us on TikTok @skytalkers Follow us on Facebook Follow us on Instagram @skytalkerspodcast Follow Charlotte on Twitter/X @crerrity Follow Caitlin on Twitter/X @caitlinplesher Email us! hello@skytalkers.com For ad inquiries please email: skytalkers@58ember.com Please note this Episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this Episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Recent pay offers to teachers are seen by the Public Service Commissioner as entirely reasonable. Primary teachers decided to reject its latest offer, while PPTA members are voting on the revised one. It includes increasing the number of days secondary teachers can be called back to work outside of term time. Commissioner Sir Brian Roche told Mike Hosking they have the ability to call them back for 10 more days a year, which is what's being asked. He says they're getting paid for this and just want teachers to be available for career development when students aren't at school. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyes by Hand: Prosthetics of Art and Healing (MIT Press, 2025) is a book about artificial eyes—about the artisans and artists who make them, and about the life-changing and sometimes life-saving experience of wearing them, as author Dan Roche has done for 15 years. Eye making is done by hand, for one person at a time, by a very small number of ocularists (fewer than 200 in the US); it is a slow, intricate, and unusually intimate process of molding, fitting, and painting that brings ocularist and patient together for many hours or even days.In Eyes by Hand, Dr. Roche describes the craft that goes into the making of an eye that looks uncannily real, as well as the psychological and emotional healing that such service brings to someone who has suffered the very visible trauma of eye loss—a loss that can go to the heart of self-identity.In an engaging, frankly fascinating fashion, Roche captures the intricacies of a profession whose techniques and culture have been remarkably consistent for 200 years. He explores, too, how that profession may now be facing a digital transformation in the form of scan-print-mail possibilities. Such a change might make prosthetic eyes more easily and cheaply available, though it may also risk the aesthetic qualities and intimate connection fundamental to the process of healing. This interview was conducted by Dr. Miranda Melcher whose book focuses on post-conflict military integration, understanding treaty negotiation and implementation in civil war contexts, with qualitative analysis of the Angolan and Mozambican civil wars. You can find Miranda's interviews on New Books with Miranda Melcher, wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Healthcare systems continue to face intense workforce challenges, with nursing at the center of concern. According to the U.S. Bureau of Labor Statistics, employment of registered nurses is expected to grow 5% between 2024 and 2034—faster than the average growth across all jobs in the U.S. economy. While this growth reflects rising demand for healthcare services, especially among an aging population and patients managing chronic conditions, the greater challenge lies in workforce turnover. On average, more than 189,000 nursing positions will need to be filled each year to replace those leaving the profession due to retirements or career changes. Combined with post-pandemic burnout and competition from other sectors, these trends make workforce development, recruitment, and retention a critical priority for healthcare leaders across hospitals, outpatient centers, and home or residential care settings.How can healthcare leaders and academic partners work together to build a future-ready workforce that supports both patient care and long-term system stability?On this episode of I Don't Care by Dr. Kevin Stevenson, guest Geoffrey Roche, Senior Vice President for Healthcare Solutions at Risepoint, explores strategies for strengthening the pipeline of nurses, technologists, and other clinical roles. The conversation spans Roche's career in healthcare administration, academia, and EdTech, and highlights innovative models of workforce development from both the U.S. and abroad.Key Points from the Conversation…Early Engagement: Initiatives such as healthcare-focused high schools and apprenticeship programs can ignite interest before college and strengthen long-term retention.Breaking Barriers: Addressing waiting lists in clinical programs and offering paid roles for students creates a stronger path to licensure.Transformational Leadership: Healthcare systems need leaders invested in long-term workforce development, not transactional approaches focused only on immediate productivity.Geoffrey M. Roche is a national leader in healthcare workforce development, currently serving as Senior Vice President for Healthcare Solutions at Risepoint. He previously directed workforce strategy at Siemens Healthineers and held executive roles at Harrisburg University, Core Education, and Dignity Health Global Education, where he advanced health equity and built scalable education-to-workforce pipelines. Roche is also an adjunct professor and Forbes Business Council member, recognized for his expertise in leadership, healthcare innovation, and academic-industry collaboration.

Russ Branzell, President and CEO of CHIME, sits down with Dr. Okan Ekinci, CMIO & Global Head of Digital Technology at Roche Information Solutions, to explore the evolving roles of digital health in one of the world's largest biotech organizations. From aligning diagnostics and pharmaceutical innovation to enhancing cybersecurity and unlocking AI's clinical potential, Dr. Ekinci shares how Roche is navigating digital transformation in healthcare on a global scale. This insightful conversation also addresses the cultural and leadership shifts necessary to sustain innovation and ensure long-term impact in healthcare and life sciences.Key Takeaways:Key challenges and opportunities in integrating diagnostic data with treatment decisions.Emerging frameworks to overcome data silos and drive clinical interoperability.Biotech-specific cybersecurity threats and strategies for balancing protection with innovation.The top technologies transforming patient care and shaping the future of precision medicine.Leadership imperatives for building a culture of sustainable innovation in life sciences.

When Google reversed its decision to deprecate third-party cookies, the first word in ID5 CEO Mathieu Roche's mind was an expletive. But it doesn't really matter what happens with cookies on Chrome anymore. “Most of the industry has moved past the notion that cookies were good enough to target and measure advertising on the web,” Roche says.

This week we are so excited to bring you our conversation with Laurent Hopman and Renaud Roche, the creators of the upcoming incredible new graphic novel LUCAS WARS. If you don't know about it already, this book tells the epic story of the making of the original STAR WARS in a way never done before and we can't get enough of it. Hear all about how this book came to be, what's to come next and some big folks who've also loved the book. So get on your bike to pick up that TPM bootleg, listen today and celebrate the love! JOIN THE BLAST POINTS ARMY and SUPPORT BLAST POINTS ON PATREON! NEW ANDOR SEASON 2 EPISODE COMMENTARIES! COMMENTARIES FOR EVERY SKELETON CREW EPISODE! NEW EMPIRE STRIKES BACK COMMENTARY! Theme Music! downloadable tunes from episodes! Extra goodies! and so much MORE! www.patreon.com/blastpoints Blast Points T-SHIRTS are now available! Represent your favorite podcast everywhere you go! Get logo shirts while supplies last! Perfect for conventions, dates, formal events and more! Get them here: www.etsy.com/shop/Gibnerd?section_id=21195481 If you dug the show, please leave BLAST POINTS a review on iTunes, Spotify and share the show with friends! If you leave an iTunes review, we will read it on a future episode! Honestly! Talk to Blast Points on twitter at @blast_points "Like" Blast Points on Facebook Join the Blast Points Super Star Wars Chill Group here www.facebook.com/groups/ BlastPointsGroup/ we are also on Instagram! Wow! www.instagram.com/blastpoints Your hosts are Jason Gibner & Gabe Bott! contact BLAST POINTS at : contact@blastpointspodcast.com May the Force be with you, always! This podcast is not affiliated in any way with Lucasfilm Ltd. LLC, The Walt Disney Company, or any of their affiliates or subsidiaries.

(00:00) We start talking about Kowloon, but we quickly shift gears to Joe Murray’s knowledge of food! (18:54) Are the Boston Red legit or are they pretenders? Joe and Roche debate! (32:48) Looks like Bill Belichick is selling some of his real estate on Nantucket. (PLEASE be aware timecodes may shift up to a few minutes due to inserted ads) CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

US-Präsident Trump will tiefere Medikamentenpreise und droht mit Zöllen. Nutzen Roche, Novartis und Co. den US-Markt aus? Und, warum fällt es der Branche so schwer Preise zu senken, angesichts der hohen Gewinne und Gehälter? Kritische Fragen an Interpharma-Geschäftsführer René Buholzer. Ergänzend zum Tagesgespräch finden Sie jeden Samstag in unserem Kanal die aktuelle Samstagsrundschau. Die Schweizer Pharma-Industrie steht gleich unter mehrfachem Druck aus den USA: einerseits soll sie die Preise senken für Medikamente in den USA und vermehrt im Land produzieren. Die Industrie hat Milliardeninvestitionen angekündigt, doch dem US-Präsidenten reicht das nicht. Bis Ende September soll die Industrie darlegen, wie sie die Medikamentenpreise, die teilweise ein Mehrfaches über denjenigen in Europa inklusive der Schweiz liegen, senken will. Gelingt das nicht drohen der Branche hohe Zölle. Die Hälfte aller Schweizer Pharma-Exporte gehen in die USA. Wie konnte die Branche so abhängig werden von einem Markt? Warum soll es trotz der hohen Margen im Geschäft nicht möglich sein, die Preise in den USA zu senken, ohne sie in Europa anzuheben? Was hat die Schweiz von Roche, Novartis und Co. tatsächlich? Und, nutzt die Branche die aktuelle Situation, um alte Forderungen nach weniger Regulierung durchzubringen? René Buholzer, der Chef von Interpharma, dem Verband der forschenden Pharmafirmen in der Schweiz, nimmt Stellung in der Samstagsrundschau bei Klaus Ammann.

BlackRock CEO Larry Fink has been appointed interim co-chair of the World Economic Forum, alongside Roche's André Hoffmann, as the organization recalibrates its governance model. It appears the old WEF needs a makeover, as many of the proposals they have been making are now facing defiance. State socialists and stockholder capitalists are now being undermined because of the bullishness from the Trump administration and others who are no longer convinced that their form of world government is key to sustainability models. The goal of the World Economic Forum is to weaponize the future and legitimize a New World Order. We are in a global ideological war between freedom and slavery. Listen to Ground Zero with Clyde Lewis M-F from 7-10 pm, pacific time on groundzeroplus.com. Call in to the LIVE show at 503-225-0860.

Networking for Introverts Who'd Rather Get a Root Canal I Greg Roche Networking advice was built for extroverts. Go to events. Make small talk. Collect business cards. For introverts, it feels like punishment. Exhausting. Fake. Pointless. Greg Roche—known as The Introverted Networker—disagrees. He's living proof you can grow a powerful network without awkward icebreakers, or pretending to be someone you're not. In this conversation, we expose the myths keeping executives stuck—and the truths that set introverts free: Why “I don't have time to network” is a myth How 15 minutes a day beats every networking event How to be “easy to help” so people actually follow through The mic drop: The more connected we get through technology, the less connected we are as humans—because we've outsourced our humanness to tech Plus, a simple, immediate action to restart your network today This isn't about becoming someone you're not. It's about using what makes you different to your advantage—and reclaiming the kind of human connection technology will never replace. Whether you're an introvert who dreads networking—or an extrovert who's been doing it wrong—you'll walk away with a playbook that actually works. Connect with Greg Roche: https://www.linkedin.com/in/gregsroche/ Get his book “The Fast and Easy Guide To Networking For Introverts” here If this episode hit home, do us a solid: leave a review on Apple Podcasts. It helps the show grow, and it helps more executives discover how to thrive in the hidden job market.

Billions are being poured into healthcare AI, yet most innovations never make it past pilot projects. Why? And more importantly—how do we fix it? In this episode of Med Tech Gurus, we sit down with Marco Smit, serial entrepreneur, life sciences executive, and AI commercialization expert. With leadership experience at Roche, Genentech, Gesund.ai, CareSyntax, and now Domelabs.ai, Marco has seen the full spectrum of healthcare AI—from hype to hard-earned success. He shares why so many organizations fall victim to “pilotitis”, the critical role of AI governance, and how startups and health systems can build scalable, evidence-driven solutions that actually deliver ROI. From navigating the complex regulatory landscape to choosing the right investors and partners, Marco offers a pragmatic playbook for moving AI from the lab to real clinical impact. Whether you're a startup founder, health system innovator, or medtech investor, this episode is packed with actionable insights on avoiding hype, accelerating adoption, and building AI solutions that last.

What happens when bureaucracy — the very operating system of most companies — becomes the biggest barrier to innovation, agility, and human potential?In this episode of The Conscious Capitalists' Summer Series, hosts Timothy Henry and Kate Adams speak with Michele Zanini, co-author of the Wall Street Journal bestseller Humanocracy and global expert on management innovation. Together, they explore how organizations can move beyond outdated, control-heavy structures to thrive in a future defined by radical uncertainty, technological disruption, and human ingenuity.Michele takes us inside bold organizational experiments — from Haier's micro-enterprise model in China to Buurtzorg's nurse-led healthcare revolution in the Netherlands — and explains how even giants like Roche are dismantling bureaucracy to become more agile and resilient. His message: organizations that unleash human creativity and distribute leadership will outpace those clinging to industrial-age hierarchy.This isn't just a conversation about management theory — it's a roadmap for building human-centered, future-ready companies that thrive in disruption and unlock the full potential of their people.Listeners will gain insights into:Why traditional bureaucratic models are collapsing — and what's replacing themHow Haier built an internal marketplace of micro-enterprises to fuel innovationBuurtzorg's “humanity over bureaucracy” approach to healthcare at scaleHow Roche transformed by shifting from command-and-control to empowermentThe principle of freedom within a framework — and how to apply itWhy unleashing human creativity is the ultimate competitive advantagePractical steps for leaders to future-proof their organizationsWhether you're a CEO fighting inertia, a startup founder designing for scale, or a leader ready to reimagine culture and structure, this episode offers powerful insights into how to build organizations that are truly capable of thriving into the future.**If you enjoy this podcast, would you consider leaving a review on Apple Podcasts/iTunes? It takes only a few seconds and greatly helps us get our podcast out to a wider audience.Please subscribe on Apple Podcasts / Spotify / Stitcher, or wherever you get your podcasts.For transcripts and show notes, please go to: https://www.theconsciouscapitalists.comThis show is presented by Conscious Capitalism, Inc. (https://www.consciouscapitalism.org/) and is produced by Rainbow Creative (https://www.rainbowcreative.co/) with Matthew Jones as Executive Producer, Rithu Jagannath as Lead Producer, and Nathan Wheatley as Editor.Thank you for your support!- Timothy & Kate

Join Bill Nowicki as he delves into the compelling life of Patrick Roche—a submariner shaped by family tradition, personal responsibility, and decades of experience beneath the waves. From growing up in a Navy family to serving on both diesel boats and missile submarines, Patrick shares intimate reflections on family, service, resilience, and camaraderie in the US Navy's Silent Service.   ### Highlights & Key Points **[00:00:00] - Beginnings in Groton & Naval Heritage** - Patrick grew up in Groton, Connecticut, with his father serving on submarines.   - Graduated high school in 1965; influenced by his father's Navy career.   - Joined the Navy after moving to San Diego (“I guess that's where I got the…”)   - Family tradition: Patrick and his father served together on the USS Ronquil (SS-396), completing three WestPac deployments to Japan and Vietnam.   **[00:03:00] - Life Aboard with Family** - Served with his father but led separate lives aboard; father was a chief quartermaster.   - Never faced negative bias due to his father's position.   Liberty meant different things for each—dad to the chief's club, Patrick and friends to the beach.   **[00:05:00] - Family Life & Responsibility** - Married at age 18, became a father early.   - Now the proud father of four daughters, eight grandchildren, and thirteen great-grandchildren.   - Emphasizes responsibility and “growing up quickly” as a driving force behind his life choices. **[00:09:00] - Naval Career & Historic Moments** - Started as a fireman apprentice with a guaranteed school for submariners.   - Went from diesel to nuclear ballistic missile submarines (SSBNs), including the USS Theodore Roosevelt (SSBN-600).   **[00:12:00] - Life and Duties on Submarines** - Served as an interior communications electrician (“IC man”), specializing as a gyro technician (explains the importance of gyros for navigation and missile launches).   - Patrolled with the George Bancroft (SSBN-643); recalls the predictability of SSBN rotations—three months on, three months off.   **[00:13:00] - Homecomings & Family Dynamics** - Kept family routines stable by letting his wife handle finances and household matters. - No issues adjusting to or from life at sea; credits strong partnership with his wife.   **[00:15:00] - Submarine Evolutions & Technological Changes** - Comments on advancements from older boats to modern fast attacks and Virginia-class submarines. - Describes watchstanding: battle helmsman responsibilities, auxiliary duties, and the unique experience of bunking arrangements.   **[00:19:00] - Challenges & Close Calls** - Survived a major flooding incident on the Roosevelt due to a head valve left open during snorkeling—highlights the ever-present dangers of submarine duty (“…we were down at 80-90 feet with the head valve open…”).   **[00:20:00] - Advancement, Brotherhood & Initiations** - Rose through the ranks to Chief in 12 years; shares stories of chief initiation rites. - Reminisces about camaraderie, qualification processes, and the support systems in place—especially as a “legacy” submariner.   **[00:24:00] - Civilian Career & Life After Service** - Transitioned to civilian roles with NAVSEA (Supervisor Shipbuilding), working in San Diego, New Orleans, and Bath, Maine. - Reflects on moving frequently for assignments, supervising ship construction.   **[00:25:00] - Retirement & Reflections** - Currently resides in Gales Ferry, Connecticut, after retiring 10 years ago. - Considers returning to Maine for its beauty and tranquility. - Stresses the importance of staying in touch with Navy friends and the legacy of the submarine community.   **[00:27:00] - The Holland Club & Submarine Brotherhood** - Member of the US Submarine Veterans' Holland Club—honoring 50+ years of qualification. - Describes the meaning of these traditions and the enduring bonds among submariners.   **[00:29:00] - Lasting Partnerships** - Acknowledges the unwavering support of his wife, Barbara, throughout their 60 years of marriage. - Offers closing reflections on the rewards of naval service and maintaining life-long friendships.   ---   ### Notable Quotes: - “I had a responsibility and had to do it.” - “People treated you a lot different, too, when you're not dink (delinquent in qualifications).” - “I just enjoyed being on the boats—wouldn't trade it for anything.” - “She [his wife] is a winner. Sixty years coming up in December.”   ---   ### Listen For: - Insights into multi-generational Navy life (00:00:00–00:04:00) - Early marriage and parenting in the military (00:05:00–00:07:00) - Historic submarine incidents (00:09:00–00:10:00) - Submarine technology and daily operations (00:12:00–00:16:00) - The legendary Holland Club tradition (00:27:00)   ---   ### Closing   **Want to hear more voices from beneath the waves? Subscribe and leave us a review!**   **Got a story to share, or questions for a guest? Email us or visit our site to connect.**   ---   **Contact & Resources:**   - Want to learn about the Holland Club? [USSVI Holland Club](https://www.ussvi.org/) - More about the Nautilus Memorial: [Submarine Force Museum](https://www.ussnautilus.org/)